Provided by Tiger Fintech (Singapore) Pte. Ltd.

NKGEN BIOTECH INC

0.1410
+0.00090.64%
Volume:11.75K
Turnover:1.59K
Market Cap:6.34M
PE:-0.07
High:0.1796
Open:0.1401
Low:0.1320
Close:0.1401
Loading ...

Company Profile

Company Name:
NKGEN BIOTECH INC
Exchange:
PINK
Establishment Date:
2017
Employees:
63
Office Location:
3001 Daimler Street,Santa Ana,California,United States
Zip Code:
92705
Fax:
- -
Introduction:
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.